Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MV-NIS + mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Mayo Clinic
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intraperitoneal, Intravenous
01
Overview
MV-NIS + mesenchymal stem cells is an investigational advanced therapy medicinal product (ATMP) that utilizes mesenchymal stem cells (MSCs) as "Trojan horse" delivery vehicles for an oncolytic measles virus. The virus, a modified Edmonston strain (MV), is engineered to express the human sodium-iodide symporter (NIS), which allows for non-invasive monitoring of viral spread via PET or SPECT imaging and enables targeted radiotherapy. By loading the virus into MSCs, the therapy seeks to shield the oncolytic agent from neutralizing antibodies in the bloodstream and exploit the natural tumor-homing capabilities of the stem cells to treat metastatic disease. Once the MSCs reach the tumor microenvironment, the virus is released to selectively infect and lyse cancer cells—primarily through CD46-mediated entry—while sparing healthy tissue. This combination approach is currently being evaluated for the treatment of refractory solid tumors, most notably ovarian cancer.
- Other names
- MV-NIS-infected mesenchymal stem cellsMSC-delivered MV-NISMesenchymal stem cells loaded with MV-NIS
02
Targets
CD46 (CD46 Molecule)PVRL4 (Nectin cell adhesion molecule 4)NIS (Human sodium iodide symporter)
Beyond the preview
Go deeper on MV-NIS + mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MV-NIS + mesenchymal stem cells.